Welcome to our dedicated page for Enzo Biochem news (Ticker: ENZ), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.
Enzo Biochem, Inc. (historically ENZ on the NYSE and later ENZB on OTCQX) generated a steady stream of corporate and financial news as a life sciences company focused on labeling and detection technologies from DNA to whole cell analysis. Its disclosures highlight a portfolio of thousands of products, including antibodies, genomic probes, assays, biochemicals, and proteins that support translational research and drug development in areas such as cell biology, genomics, immunohistochemistry, and small molecule chemistry.
The company’s news flow has included quarterly and annual financial results, where Enzo reported on revenue trends in its Life Sciences division, gross margin performance, operating loss or income, and the impact of cost containment initiatives and product mix. These releases often discussed demand from drug development and cell and gene therapy market segments, as well as the use of non-GAAP measures like Adjusted net loss and Adjusted EBITDA, with reconciliations provided in accompanying tables.
Enzo’s announcements have also covered strategic and corporate actions, such as its exit from the clinical lab business, focus on life science tools, workforce and cost initiatives, and product life cycle management, including removal of non-performing SKUs and new product launches. Governance and corporate updates have included officer appointments, board changes, and shareholder meeting results.
In 2025, the news record shows important capital markets and M&A developments, including NYSE non-compliance notices, a voluntary delisting from the NYSE, transfer of trading to OTCQX, and the subsequent agreement and completion of a merger with Bethpage Parent, Inc., after which Enzo became a wholly owned subsidiary and its shares ceased trading. For readers reviewing ENZ or ENZB news, this page serves as a historical archive of earnings releases, strategic reviews, listing changes, and merger-related communications.
Enzo Biochem (NYSE:ENZ) is set to announce its fourth quarter and fiscal year 2021 financial results on October 12, 2021, before the market opens. Following the announcement, there will be a live audio webcast and conference call at 8:30 am ET. Enzo is known for its innovations in molecular diagnostics and has a significant intellectual property portfolio. The company aims to address the evolving demands of the healthcare sector, though specifics regarding financial performance remain undisclosed in the release.
Enzo Biochem, a prominent biosciences and diagnostics firm, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. An on-demand presentation will be available for 90 days starting September 13 at 7:00 am ET on their website. Management encourages investors to schedule virtual 1-on-1 meetings during the conference. For further details, attendees can visit the H.C. Wainwright conference website.
Enzo Biochem (NYSE:ENZ) has expanded its FDA Emergency Use Authorization (EUA) for a rapid extraction method on its proprietary SARS-CoV-2 test system. This advancement reduces testing time by over one hour, enhancing throughput significantly. The method is compatible with various platforms, including Enzo's GENFLEX® system. Enzo's tests can identify emerging SARS-CoV-2 variants like Delta and Lambda, meeting rising testing demands. The company emphasizes its integrated business model, allowing quick adaptation to diagnostics needs during the COVID-19 pandemic.
Enzo Biochem (NYSE:ENZ) has partnered with CLX Health to provide rapid COVID-19 PCR testing for international travelers in New York and New Jersey. The TrustAssure™ Global Testing Platform enables online scheduling of tests with results delivered before travel. This collaboration enhances convenience for travelers, providing access to Enzo's testing sites and compliance notifications for airlines. The demand for PCR testing has shifted as international travel resumes, emphasizing the need for quick and reliable availability of test results.
Enzo Biochem reported a record third-quarter revenue of $32.8 million, marking a 94% increase year-over-year. The gross margin improved to 49% from 26%, showcasing enhanced profitability. The company achieved its third consecutive quarter of positive earnings with an EPS of $0.04, compared to a loss of ($0.21) a year prior. Adjusted EBITDA reached $2.7 million. Enzo's operational strategies have yielded an operating profit of $2.0 million, a significant turnaround from a $9.7 million loss in Q3 2020.
Enzo Biochem (NYSE:ENZ) has announced that it will report its third quarter 2021 financial results on June 9, 2021, after market close. The company will host a live audio webcast and conference call at 4:30 pm ET to discuss the results. Enzo Biochem specializes in molecular diagnostics and utilizes advanced technologies to meet growing healthcare demands. The company has a strong intellectual property portfolio that supports its innovative diagnostic platforms.
Enzo Biochem has received FDA clearance for its AMPICOLLECT™ Sample Collection kit, now authorized for COVID-19 testing under Emergency Use Authorization. The kit can be utilized with various testing platforms, including Enzo's GENFLEX® molecular diagnostic platform. This development highlights the company's integrated approach in diagnostics, addressing challenges during the pandemic, such as supply shortages. The AMPICOLLECT™ kit is part of Enzo's broader strategy to provide comprehensive diagnostic solutions and underscores its commitment to innovation and efficiency in clinical testing.
Enzo Biochem (NYSE:ENZ) will participate in the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 23rd at 10:45 am ET. Barry Weiner, President, and David Bench, CFO, will also hold virtual one-on-one meetings on March 23rd and 24th. Interested parties can contact their KeyBanc representatives for arrangements. The presentation will be live-streamed, accessible via the provided webcast link. Enzo Biochem is recognized for its innovative molecular diagnostics and diagnostic platform technologies.
Enzo Biochem reported a strong Q2 2021 with total revenue of $31.5 million, a 62% increase year-over-year, and clinical laboratory revenue up 92% to $24.0 million. The consolidated gross margin improved to 50%, a 2000 basis points year-over-year increase. Adjusted EBITDA reached $4.3 million, with EPS of $0.05, contrasting a loss of ($0.16) in Q2 2020. CEO Dr. Elazar Rabbani will transition to a scientific role, and Gary Huff was appointed as Strategic Consultant. The company is focused on growth in molecular diagnostics, leveraging its proprietary GENFLEX™ platform.
Enzo Biochem, Inc. (NYSE:ENZ) will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. EST on March 9, 2021. A replay will be accessible via the 'News & Events' section of the Enzo Biochem website post-conference. Enzo Biochem is a pioneer in molecular diagnostics and offers advanced diagnostic platform technologies. Their broad intellectual property portfolio supports their innovative products and services in the rapidly growing healthcare sector.